Strategic Investments Beyond Celiac is actively investing through Beyond Celiac Investments (BCI) in early-stage biotech and cell/gene therapy companies, presenting a potential channel for co-investment opportunities, partnerships, and deal sourcing with startups aligning to celiac disease therapeutics.

Fundraising & Partnerships Recent financing activity shows external investor interest in celiac-focused ventures (e.g., Tolerance Bio, RheumaGen) with Beyond Celiac participating, indicating openness to strategic collaborations, grant-like funding, and venture philanthropy aligned with product development milestones.

Clinical & Trials Leadership changes in clinical and scientific roles (COO promoted to President, new Chief Medical Officer and Chief Scientific Officer appointments) suggest a strong focus on accelerating clinical trial recruitment and research, presenting opportunities to offer trial services, sites, patient recruitment, and data collaboration.

Advocacy to Analytics With a strong patient-advocacy foundation and a technical stack spanning CRM, analytics, and e-commerce platforms, there is potential to propose partnerships for patient registries, digital engagement, trial matching, and data analytics solutions that support research and outreach.

Market Positioning As a mid-sized research-oriented nonprofit with a revenue range of tens of millions and a focus on moving beyond dietary management to therapeutic development, Beyond Celiac presents opportunities to license or co-develop patient-centered treatment education programs, clinical support tools, and parallel funding models.